Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    November 2021
  1. JAFFE S
    Legal challenges threaten Biden's COVID-19 vaccine rule.
    Lancet. 2021;398:1863-1864.
    >> Share

  2. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
    Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
    >> Share

  3. PAVORD S, Scully M, Lester W, Makris M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
    Lancet. 2021;398:1801.
    >> Share

  4. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
    Lancet. 2021;398:1801-1802.
    >> Share

  5. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
    Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
    >> Share

  6. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
    Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
    >> Share

  7. LI JX, Zhu FC
    Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.
    >> Share

  8. ALVES L
    Health experts welcome Brazil COVID-19 inquiry findings.
    Lancet. 2021;398:1674-1675.
    >> Share

  9. ORTIZ JR, Neuzil KM
    The value of vaccine programme impact monitoring during the COVID-19 pandemic.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.
    >> Share

  10. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    >> Share

  11. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    >> Share

    October 2021
  12. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    >> Share

  13. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.
    >> Share

  14. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    >> Share

  15. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.
    >> Share

  16. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.
    >> Share

    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.
    >> Share

  18. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.
    >> Share

    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.
    >> Share

  20. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.
    >> Share

  21. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    >> Share

    September 2021
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.
    >> Share

  23. SHARFSTEIN JM, Callaghan T, Carpiano RM, Sgaier SK, et al
    Uncoupling vaccination from politics: a call to action.
    Lancet. 2021 Sep 16. pii: S0140-6736(21)02099.
    >> Share

  24. KRAUSE PR, Fleming TR, Peto R, Longini IM, et al
    Considerations in boosting COVID-19 vaccine immune responses.
    Lancet. 2021 Sep 14. pii: S0140-6736(21)02046.
    >> Share

  25. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    >> Share

    The race to make a COVID-19 vaccine.
    Lancet. 2021;398:832-833.
    >> Share

    The long road ahead for COVID-19 vaccination in Africa.
    Lancet. 2021;398:827-828.
    >> Share

  28. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    >> Share

    Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01817.
    >> Share

  30. KASEJE N, Walcott D
    Global youth advocating for COVID-19 vaccines for all.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01994.
    >> Share

  31. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    >> Share

    August 2021
  32. LANGLOIS EV, Dey T, Shah MG
    More than honour, humanitarian health-care workers need life-saving protection.
    Lancet. 2021;398:729-730.
    >> Share

  33. BEHRENS GM, Cossmann A, Stankov MV, Nehlmeier I, et al
    SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.
    Lancet. 2021 Aug 17. pii: S0140-6736(21)01891.
    >> Share

    Haiti's health woes intensify.
    Lancet. 2021;398:567.
    >> Share

  35. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.
    Lancet. 2021;398:577-578.
    >> Share

  36. CARR EJ, Wu M, Harvey R, Wall EC, et al
    Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
    Lancet. 2021 Aug 12. pii: S0140-6736(21)01854.
    >> Share

  37. LLOYD-SHERLOCK P, Lasco G, McKee M, Perianayagam A, et al
    Does vaccine ageism amount to gerontocide?
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01689.
    >> Share

  38. KALAFAT E, Magee LA, von Dadelszen P, O'Brien P, et al
    SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity.
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01756.
    >> Share

  39. CRUMP JA, Oo WT
    Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01340.
    >> Share

  40. QADRI F, Khanam F, Liu X, Theiss-Nyland K, et al
    Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01124.
    >> Share

  41. PRIESEMANN V, Balling R, Bauer S, Beutels P, et al
    Towards a European strategy to address the COVID-19 pandemic.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01808.
    >> Share

  42. LEE EJ, Lee AI
    Cerebral venous sinus thrombosis after vaccination: the UK experience.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01788.
    >> Share

  43. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    >> Share

  44. LIU X, Shaw RH, Stuart ASV, Greenland M, et al
    Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01694.
    >> Share

    Optimising SARS-CoV-2 vaccination schedules.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01729.
    >> Share

    July 2021
  46. SHROTRI M, Navaratnam AMD, Nguyen V, Byrne T, et al
    Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
    Lancet. 2021;398:385-387.
    >> Share

  47. KAMPMANN B, Okomo U
    COVID-19 vaccines for children in LMICs: another equity issue.
    Lancet. 2021 Jul 30. pii: S0140-6736(21)01748.
    >> Share

  48. MAKONI M
    Social unrest disrupts South African health care.
    Lancet. 2021;398:287.
    >> Share

  49. REDJOUL R, Le Bouter A, Beckerich F, Fourati S, et al
    Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
    Lancet. 2021;398:298-299.
    >> Share

    COVID-19 in Africa: a lesson in solidarity.
    Lancet. 2021;398:185.
    >> Share

  51. DANOVARO-HOLLIDAY MC, Kretsinger K, Gacic-Dobo M
    Measuring and ensuring routine childhood vaccination coverage.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01228.
    >> Share

  52. CAUCHEMEZ S, Bosetti P, Kiem CT, Mouro V, et al
    Education and mental health: good reasons to vaccinate children.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01453.
    >> Share

  53. CAUSEY K, Fullman N, Sorensen RJD, Galles NC, et al
    Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01337.
    >> Share

  54. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00984.
    >> Share

    COVID-19 in Latin America-emergency and opportunity.
    Lancet. 2021;398:93.
    >> Share

  56. TANRIOVER MD, Doganay HL, Akova M, Guner HR, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Lancet. 2021 Jul 8. pii: S0140-6736(21)01429.
    >> Share

  57. GURDASANI D, Drury J, Greenhalgh T, Griffin S, et al
    Mass infection is not an option: we must do more to protect our young.
    Lancet. 2021 Jul 7. pii: S0140-6736(21)01589.
    >> Share

    June 2021
  58. WALL EC, Wu M, Harvey R, Kelly G, et al
    AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
    Lancet. 2021 Jun 28. pii: S0140-6736(21)01462.
    >> Share

  59. SMITH MJ
    What constitutes success in the roll-out of COVID-19 vaccines?
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01244.
    >> Share

  60. DUARTE-SALLES T, Prieto-Alhambra D
    Heterologous vaccine regimens against COVID-19.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01442.
    >> Share

  61. BOROBIA AM, Carcas AJ, Perez-Olmeda M, Castano L, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01420.
    >> Share

    Protecting refugees during the COVID-19 pandemic.
    Lancet. 2021;397:2309.
    >> Share

    Five priorities for universal COVID-19 vaccination.
    Lancet. 2021 Jun 17. pii: S0140-6736(21)01371.
    >> Share

  64. SHEIKH A, McMenamin J, Taylor B, Robertson C, et al
    SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
    Lancet. 2021 Jun 14. pii: S0140-6736(21)01358.
    >> Share

  65. GAYTHORPE KAM, Toor J, Echeverria-Londono S, Li X, et al
    Vaccines can save children with non-preventable diseases - Authors' reply.
    Lancet. 2021;397:2251.
    >> Share

  66. SAHA S, Saha SK
    Vaccines can save children with non-preventable diseases.
    Lancet. 2021;397:2250.
    >> Share

  67. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply.
    Lancet. 2021;397:2249-2250.
    >> Share

  68. ROBERTSON JFR, Sewell HF
    COVID-19 vaccine efficacy data: solid enough to delay second dose?
    Lancet. 2021;397:2248-2249.
    >> Share

  69. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.
    Lancet. 2021;397:2248.
    >> Share

  70. MCQUADE ETR, Platts-Mills JA
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
    Lancet. 2021;397:2247-2248.
    >> Share

  71. NASSER A, Zakham F
    A strategy for SARS-CoV-2 vaccination in Yemen.
    Lancet. 2021;397:2247.
    >> Share

  72. GUETL K, Gary T, Raggam RB, Schmid J, et al
    SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.
    Lancet. 2021 Jun 11. pii: S0140-6736(21)01238.
    >> Share

  73. BOLLYKY TJ, Murray CJL, Reiner RC Jr
    Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.
    Lancet. 2021 Jun 8. pii: S0140-6736(21)01323.
    >> Share

  74. KUMAR A, Bernasconi V, Manak M, de Almeida Aranha AP, et al
    The CEPI centralised laboratory network: supporting COVID-19 vaccine development.
    Lancet. 2021;397:2148-2149.
    >> Share

  75. WALL EC, Wu M, Harvey R, Kelly G, et al
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01290.
    >> Share

  76. NNAJI CA, Ndwandwe D, Lesosky M, Mahomed H, et al
    Tackling missed opportunities for vaccination in a new era of immunisation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01226.
    >> Share

  77. KOSAKA M, Hashimoto T, Ozaki A, Tanimoto T, et al
    Delayed COVID-19 vaccine roll-out in Japan.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01220.
    >> Share

  78. FORMAN R, Jit M, Mossialos E
    Divergent vaccination policies could fuel mistrust and hesitancy.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)01106.
    >> Share

    May 2021
  79. MAKONI M
    Africa's need for more COVID-19 clinical trials.
    Lancet. 2021;397:2037.
    >> Share

  80. JAWAD NK, Taweeleh LA, Elharake JA, Khamis N, et al
    Refugee access to COVID-19 vaccines in Lebanon.
    Lancet. 2021;397:1884.
    >> Share

    What next for a COVID-19 intellectual property waiver?
    Lancet. 2021;397:1871-1872.
    >> Share

  82. LOYO ESL, Gonzalez MJ, Esparza J
    Venezuela is collapsing without COVID-19 vaccines.
    Lancet. 2021;397:1806.
    >> Share

    Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?
    Lancet. 2021;397:1804-1805.
    >> Share

  84. TORRES I, Lopez-Cevallos D, Artaza O, Profeta B, et al
    Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments.
    Lancet. 2021;397:1804.
    >> Share

  85. HOUSTON AR, Murthy S
    Canada is no global health leader on COVID-19 vaccine equity.
    Lancet. 2021;397:1803.
    >> Share

  86. HOLT E
    Serbia begins paying citizens to receive a COVID-19 vaccine.
    Lancet. 2021;397:1793.
    >> Share

  87. GENC K
    COVID-19 in Turkey: a nation on edge.
    Lancet. 2021;397:1794-1796.
    >> Share

  88. JHA P, Jamison DT, Watkins DA, Bell J, et al
    A global compact to counter vaccine nationalism.
    Lancet. 2021 May 14. pii: S0140-6736(21)01105.
    >> Share

  89. KUPPALLI K, Gala P, Cherabuddi K, Kalantri SP, et al
    India's COVID-19 crisis: a call for international action.
    Lancet. 2021 May 14. pii: S0140-6736(21)01121.
    >> Share

  90. SHAW RH, Stuart A, Greenland M, Liu X, et al
    Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Lancet. 2021 May 12. pii: S0140-6736(21)01115.
    >> Share

  91. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV
    Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.
    Lancet. 2021 May 12. pii: S0140-6736(21)00894.
    >> Share

  92. MOORTHY V, Binka F
    R21/Matrix-M: a second malaria vaccine?
    Lancet. 2021 May 5. pii: S0140-6736(21)01065.
    >> Share

  93. DATOO MS, Natama MH, Some A, Traore O, et al
    Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Lancet. 2021 May 5. pii: S0140-6736(21)00943.
    >> Share

  94. HAAS EJ, Angulo FJ, McLaughlin JM, Anis E, et al
    Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Lancet. 2021 May 5. pii: S0140-6736(21)00947.
    >> Share

  95. LESHEM E, Wilder-Smith A
    COVID-19 vaccine impact in Israel and a way out of the pandemic.
    Lancet. 2021 May 5. pii: S0140-6736(21)01018.
    >> Share

  96. BHUYAN A
    Experts criticise India's complacency over COVID-19.
    Lancet. 2021;397:1611-1612.
    >> Share

    April 2021
  97. BURKI T
    Statelessness in the COVID-19 pandemic.
    Lancet. 2021;397:1529-1530.
    >> Share

    2021: the beginning of a new era of immunisations?
    Lancet. 2021;397:1519.
    >> Share

  99. HALL VJ, Foulkes S, Saei A, Andrews N, et al
    COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00790.
    >> Share

  100. LESHEM E, Lopman BA
    Population immunity and vaccine protection against infection.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00870.
    >> Share

  101. DEAN N
    Hospital admissions due to COVID-19 in Scotland after one dose of vaccine.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00765.
    >> Share

  102. VASILEIOU E, Simpson CR, Shi T, Kerr S, et al
    Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00677.
    >> Share

  103. KHAN MS, Ali SAM, Adelaine A, Karan A, et al
    Rethinking vaccine hesitancy among minority groups.
    Lancet. 2021 Apr 21. pii: S0140-6736(21)00938.
    >> Share

  104. ALVES L
    Brazilian ICUs short of drugs and beds amid COVID-19 surge.
    Lancet. 2021;397:1431-1432.
    >> Share

  105. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    >> Share

  106. MUSTER V, Gary T, Raggam RB, WOlfler A, et al
    Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00871.
    >> Share

  107. MFINANGA SG, Mnyambwa NP, Minja DT, Ntinginya NE, et al
    Tanzania's position on the COVID-19 pandemic.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00678.
    >> Share

  108. CAPUA I, Giaquinto C
    The unsung virtue of thermostability.
    Lancet. 2021;397:1346.
    >> Share

  109. ALI SN, Hanif W, Patel K, Khunti K, et al
    Ramadan and COVID-19 vaccine hesitancy-a call for action.
    Lancet. 2021 Apr 7. pii: S0140-6736(21)00779.
    >> Share

  110. D'SOUZA RS, Wolfe I
    COVID-19 vaccines in high-risk ethnic groups.
    Lancet. 2021 Apr 1. pii: S0140-6736(21)00624.
    >> Share

    March 2021
  111. EMARY KRW, Golubchik T, Aley PK, Ariani CV, et al
    Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00628.
    >> Share

  112. OSTERGAARD SD, Schmidt M, Horvath-Puho E, Thomsen RW, et al
    Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00762.
    >> Share

  113. SANDERS RW, de Jong MD
    Pandemic moves and countermoves: vaccines and viral variants.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00730.
    >> Share

  114. MYLAN S, Hardman C
    COVID-19, cults, and the anti-vax movement.
    Lancet. 2021;397:1181.
    >> Share

  115. USHER AD
    Uncertainties over EU COVID-19 vaccine sharing scheme.
    Lancet. 2021;397:1171.
    >> Share

  116. KLUGE H, McKee M
    COVID-19 vaccines for the European region: an unprecedented challenge.
    Lancet. 2021 Mar 25. pii: S0140-6736(21)00709.
    >> Share

  117. Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00708.
    >> Share

  118. CHANDAN JS, Chandan JK
    Considering gender-based violence in vaccine prioritisation strategies.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00532.
    >> Share

  119. KRISTIANSEN PA, Page M, Bernasconi V, Mattiuzzo G, et al
    WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
    Lancet. 2021 Mar 23. pii: S0140-6736(21)00527.
    >> Share

  120. KARIM SSA
    Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00468.
    >> Share

  121. MUNDT AP
    Assessing government responsibility for COVID-19 deaths.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00529.
    >> Share

  122. SAAH AJ, Munoz N
    Control vaccine formulation - Authors' reply.
    Lancet. 2021;397:1062.
    >> Share

  123. DOSHI P, Hong K, Jefferson T, Jones M, et al
    Control vaccine formulation.
    Lancet. 2021;397:1061-1062.
    >> Share

  124. JAFFE S
    Biden's first legislative victory: $1.9 trillion for COVID-19.
    Lancet. 2021;397:1047-1048.
    >> Share

    Myanmar's democracy and health on life support.
    Lancet. 2021;397:1035.
    >> Share

  126. BOZORGMEHR K, Jahn R, Stuckler D, McKee M, et al
    Free licensing of vaccines to end the COVID-19 crisis.
    Lancet. 2021 Mar 18. pii: S0140-6736(21)00467.
    >> Share

  127. KRIEGER N, Waterman PD, Chen JT, Testa C, et al
    Missing again: US racial and ethnic data for COVID-19 vaccination.
    Lancet. 2021 Mar 17. pii: S0140-6736(21)00465.
    >> Share

  128. HOLT E
    Countries split from EU on COVID-19 vaccines.
    Lancet. 2021;397:958.
    >> Share

    Access to COVID-19 vaccines: looking beyond COVAX.
    Lancet. 2021;397:941.
    >> Share

  130. DEVI S
    Health in Syria: a decade of conflict.
    Lancet. 2021;397:955-956.
    >> Share

  131. STEINBERG J, Thomas A, Iravani A
    (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
    Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.
    >> Share

    Robin Shattock: novel vaccine developer.
    Lancet. 2021;397:870.
    >> Share

  133. HUNG IFN, Poland GA
    Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
    Lancet. 2021;397:854-855.
    >> Share

  134. VIJAYASINGHAM L, Bischof E, Wolfe J
    Sex-disaggregated data in COVID-19 vaccine trials.
    Lancet. 2021 Mar 5. pii: S0140-6736(21)00384.
    >> Share

    February 2021
  135. BATNIJI R
    Historical evidence to inform COVID-19 vaccine mandates.
    Lancet. 2021;397:791.
    >> Share

  136. CHAUVIN L
    Peruvian COVID-19 vaccine scandal spreads.
    Lancet. 2021;397:783.
    >> Share

    New WTO leader faces COVID-19 challenges.
    Lancet. 2021;397:782.
    >> Share

  138. ADEPOJU P
    Ebola returns to Guinea and DR Congo.
    Lancet. 2021;397:781.
    >> Share

  139. PRENDECKI M, Clarke C, Brown J, Cox A, et al
    Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00502.
    >> Share

  140. MANISTY C, Otter AD, Treibel TA, McKnight A, et al
    Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00501.
    >> Share

  141. Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Feb 24. pii: S0140-6736(21)00372.
    >> Share

  142. SIVA N
    Severe mental illness: reassessing COVID-19 vaccine priorities.
    Lancet. 2021;397:657.
    >> Share

  143. HYDE R
    von der Leyen admits to COVID-19 vaccine failures.
    Lancet. 2021;397:655-656.
    >> Share

  144. VOYSEY M, Costa Clemens SA, Madhi SA, Weckx LY, et al
    Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00432.
    >> Share

  145. SISA I, Noblecilla E, Orozco F
    Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00357.
    >> Share

  146. ROBERTSON JFR, Sewell HF, Stewart M
    Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00455.
    >> Share

  147. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
    Lancet. 2021 Feb 18. pii: S0140-6736(21)00448.
    >> Share

  148. SKEGG D, Gluckman P, Boulton G, Hackmann H, et al
    Future scenarios for the COVID-19 pandemic.
    Lancet. 2021 Feb 16. pii: S0140-6736(21)00424.
    >> Share

  149. MAKONI M
    Tanzania refuses COVID-19 vaccines.
    Lancet. 2021;397:566.
    >> Share

    Improving prisoner health for stronger public health.
    Lancet. 2021;397:555.
    >> Share

  151. WOUTERS OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, et al
    Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00306.
    >> Share

  152. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00388.
    >> Share

  153. FONTANET A, Autran B, Lina B, Kieny MP, et al
    SARS-CoV-2 variants and ending the COVID-19 pandemic.
    Lancet. 2021 Feb 11. pii: S0140-6736(21)00370.
    >> Share

  154. MARTIN S, Arawi T
    Ensure Palestinians have access to COVID-19 vaccines.
    Lancet. 2021 Feb 9. pii: S0140-6736(21)00190.
    >> Share

  155. BEHRENS RH, Patel V
    Avoiding shoulder injury from intramuscular vaccines.
    Lancet. 2021;397:471.
    >> Share

    Time to revise the strategy for Gavi funding of rabies vaccine?
    Lancet. 2021;397:471-472.
    >> Share

  157. LANE R
    Tahmeed Ahmed: new leader of icddr,b.
    Lancet. 2021;397:463.
    >> Share

  158. LOIZIDES U, Adisa A, de la Rica Manjavacas AL, Robertson JS, et al
    WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00099.
    >> Share

  159. MEREWOOD A, Bode L, Davanzo R, Perez-Escamilla R, et al
    Breastfeed or be vaccinated-an unreasonable default recommendation.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00197.
    >> Share

  160. CLARFIELD AM, Skorecki K, Manor O, Glick S, et al
    A COVID-19 jab in the right direction.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00310.
    >> Share

  161. JONES I, Roy P
    Sputnik V COVID-19 vaccine candidate appears safe and effective.
    Lancet. 2021 Feb 2. pii: S0140-6736(21)00191.
    >> Share

  162. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, et al
    Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
    Lancet. 2021 Feb 2. pii: S0140-6736(21)00234.
    >> Share

  163. FRIESEN P, Caplan AL, Miller JE
    COVID-19 vaccine research and the trouble with clinical equipoise.
    Lancet. 2021 Feb 1. pii: S0140-6736(21)00198.
    >> Share

    January 2021
  164. LI X, Mukandavire C, Cucunuba ZM, Echeverria Londono S, et al
    Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
    Lancet. 2021;397:398-408.
    >> Share

    Health experts slam Bolsonaro's vaccine comments.
    Lancet. 2021;397:361.
    >> Share

  166. COHEN AL, Patel MK, Cherian T
    Vaccines work: a reason for celebration and renewed commitment.
    Lancet. 2021;397:351-353.
    >> Share

    Health and care workers are owed a better future.
    Lancet. 2021;397:347.
    >> Share

  168. BLAKNEY AK, McKay PF
    Next-generation COVID-19 vaccines: here come the proteins.
    Lancet. 2021 Jan 29. pii: S0140-6736(21)00258.
    >> Share

  169. RICHMOND P, Hatchuel L, Dong M, Ma B, et al
    Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Lancet. 2021 Jan 29. pii: S0140-6736(21)00241.
    >> Share

  170. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
    Lancet. 2021 Jan 28. pii: S0140-6736(21)00242.
    >> Share

  171. WATT G, Giacaman R, Zurayk H, Bjertness E, et al
    COVID-19 vaccines for Palestinians.
    Lancet. 2021 Jan 28. pii: S0140-6736(21)00185.
    >> Share

  172. BARDAJI A, Sevene E, Cutland C, Menendez C, et al
    The need for a global COVID-19 maternal immunisation research plan.
    Lancet. 2021 Jan 25. pii: S0140-6736(21)00146.
    >> Share

  173. BHUYAN A
    India begins COVID-19 vaccination amid trial allegations.
    Lancet. 2021;397:264.
    >> Share

  174. MAKONI M
    South Africa responds to new SARS-CoV-2 variant.
    Lancet. 2021;397:267.
    >> Share

  175. USHER AD
    CEPI criticised for lack of transparency.
    Lancet. 2021;397:265-266.
    >> Share

  176. CAVALERI M, Enzmann H, Straus S, Cooke E, et al
    The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
    Lancet. 2021 Jan 13. pii: S0140-6736(21)00085.
    >> Share

  177. STAPLES JE, Alvarez AR
    Public health role for fractional dosage of yellow fever vaccine.
    Lancet. 2021;397:76-77.
    >> Share

  178. JUAN-GINER A, Kimathi D, Grantz KH, Hamaluba M, et al
    Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Lancet. 2021;397:119-127.
    >> Share

  179. GOSTIN LO, Shalala DE, Hamburg MA, Bloom BR, et al
    A global health action agenda for the Biden administration.
    Lancet. 2021;397:5-8.
    >> Share

    December 2020
  180. HARMAN S, Herten-Crabb A, Morgan R, Smith J, et al
    COVID-19 vaccines and women's security.
    Lancet. 2020 Dec 22. pii: S0140-6736(20)32727.
    >> Share

  181. CLAESON M, Hanson S
    COVID-19 and the Swedish enigma.
    Lancet. 2020 Dec 22. pii: S0140-6736(20)32750.
    >> Share

  182. SIVA N
    Experts call to include prisons in COVID-19 vaccine plans.
    Lancet. 2020;396:1870.
    >> Share

  183. BURGESS RA, Osborne RH, Yongabi KA, Greenhalgh T, et al
    The COVID-19 vaccines rush: participatory community engagement matters more than ever.
    Lancet. 2020 Dec 10. pii: S0140-6736(20)32642.
    >> Share

  184. DE COSTER I, Leroux-Roels I, Bandyopadhyay AS, Gast C, et al
    Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32541.
    >> Share

  185. SAEZ-LLORENS X, Bandyopadhyay AS, Gast C, Leon T, et al
    Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32540.
    >> Share

    Poliovirus vaccine options: another step forward.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
    >> Share

  187. ARYEETEY E, Engebretsen E, Gornitzka A, Maassen P, et al
    A step backwards in the fight against global vaccine inequities.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32596.
    >> Share

  188. KNOLL MD, Wonodi C
    Oxford-AstraZeneca COVID-19 vaccine efficacy.
    Lancet. 2020 Dec 8. pii: S0140-6736(20)32623.
    >> Share

  189. VOYSEY M, Clemens SAC, Madhi SA, Weckx LY, et al
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
    Lancet. 2020 Dec 8. pii: S0140-6736(20)32661.
    >> Share

  190. USHER AD
    South Africa and India push for COVID-19 patents ban.
    Lancet. 2020;396:1790-1791.
    >> Share

    An African plan to control COVID-19 is urgently needed.
    Lancet. 2020;396:1777.
    >> Share

  192. MULHOLLAND K, Kretsinger K, Wondwossen L, Crowcroft N, et al
    Action needed now to prevent further increases in measles and measles deaths in the coming years.
    Lancet. 2020;396:1782-1784.
    >> Share

    November 2020
    COVID-19 vaccines: no time for complacency.
    Lancet. 2020;396:1607.
    >> Share

  194. RAMASAMY MN, Minassian AM, Ewer KJ, Flaxman AL, et al
    Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Lancet. 2020 Nov 18. pii: S0140-6736(20)32466.
    >> Share

  195. ANDREW MK, McElhaney JE
    Age and frailty in COVID-19 vaccine development.
    Lancet. 2020 Nov 18. pii: S0140-6736(20)32481.
    >> Share

  196. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
    Lancet. 2020;396:1486-1487.
    >> Share

  197. LODGE A
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lancet. 2020;396:1486.
    >> Share

  198. CHAUHAN A, Agarwal A, Jaiswal N, Singh M, et al
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lancet. 2020;396:1485-1486.
    >> Share

  199. HORTON R
    Offline: Managing the COVID-19 vaccine infodemic.
    Lancet. 2020;396:1474.
    >> Share

  200. SMITH MJ, Ujewe S, Katz R, Upshur REG, et al
    Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.
    Lancet. 2020 Nov 5. pii: S0140-6736(20)32337.
    >> Share

  201. ANDERSON RM, Vegvari C, Truscott J, Collyer BS, et al
    Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
    Lancet. 2020 Nov 4. pii: S0140-6736(20)32318.
    >> Share

    October 2020
  202. HASSAN-SMITH Z, Hanif W, Khunti K
    Who should be prioritised for COVID-19 vaccines?
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32224.
    >> Share

  203. BINGHAM K
    The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world.
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32175.
    >> Share

  204. KRAUSE PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, et al
    Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32259.
    >> Share

  205. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    Use of adenovirus type-5 vectored vaccines: a cautionary tale.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32156.
    >> Share

  206. WARD BJ, Makarkov A, Seguin A, Pillet S, et al
    Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (>/=65 years): two multicentre, randomised phase 3 trials.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32014.
    >> Share

  207. POLAND GA, Ovsyannikova IG, Kennedy RB
    SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32137.
    >> Share

    First human efficacy study of a plant-derived influenza vaccine.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32010.
    >> Share

  209. MCMAHON JH, Hoy JF, Kamarulzaman A, Bekker LG, et al
    Leveraging the advances in HIV for COVID-19.
    Lancet. 2020;396:943-944.
    >> Share

    September 2020
  210. LOGUNOV DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV, et al
    Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31970.
    >> Share

  211. PEIRIS M, Leung GM
    What can we expect from first-generation COVID-19 vaccines?
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31976.
    >> Share

  212. BUCCI E, Andreev K, Bjorkman A, Calogero RA, et al
    Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31960.
    >> Share

    Global collaboration for health: rhetoric versus reality.
    Lancet. 2020;396:735.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016